Royalty Pharma plc (RPRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $64.82
- As of
Kresmion compiles this page from RPRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Royalty Pharma plc (RPRX): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
See the full RPRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RPRX on one page. Preview it with sample data, then open it live with a free account.
Preview the RPRX dossierActive events for RPRX
- high13F: funds reduced
4 tracked funds reduced RPRX this 2026Q2, institutional consensus
- high13F: funds added
3 tracked funds increased RPRX this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 78% of RPRX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +510% to RPRX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +3532% to RPRX (2026Q2)
FREE, NO ACCOUNT
Every event on RPRX, as it fires
You are seeing 5 of 17 events recorded on RPRX since 2026-06-02.
The five above landed across 2 days. The other 12 were recorded on 2 other days. 11 of the 17 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RPRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP G7709Q104 · 2026Q2 | $163.7M | 0.12% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP G7709Q104 · 2026Q2 | $108.5M | 0.15% | , |
| CITADEL ADVISORS LLCCUSIP G7709Q104 · 2026Q2 | $76M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP G7709Q104 · 2026Q2 | $29.4M | 0.01% | , |
| Bridgewater Associates, LPCUSIP G7709Q104 · 2026Q2 | $12.3M | 0.05% | , |
| Point72 Asset Management, L.P.CUSIP G7709Q104 · 2026Q2 | $6M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP G7709Q104 · 2026Q2 | $675K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RPRX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RPRX against its peers
RPRX's operating margin of 65.6% ranks in the 92nd percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | RPRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.4B USD | 2.3B USD | 55 | 18 |
| Gross margin | n/a | 86.8% | n/a | 15 |
| Operating margin | 65.6% | 10.5% | 92 | 18 |
| Net margin | 32.4% | 8.4% | 83 | 19 |
| Return on equity | 7.9% | 6.6% | 57 | 19 |
| P / E | 36.4x | 29.4x | 72 | 8 |
Peers (22): ROIV, ALNY, UTHR, INCY, GMAB, BIIB, BNTX, INSM, RVMD, ONC, EXEL, ASND, ARGX, NBIX, HALO, BBIO, NTRA, SMMT, BMRN, APGE.D, KYMR, CAI. Left out: IVBXF (no annual filing), CSLLY (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (RPRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RPRX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RPRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.